SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : CELSION CORP. (CLN was CELN) UP $.33 TO $.59 ON HUGE NEWS

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Captain James T. Kirk who wrote (493)8/29/1999 9:30:00 PM
From: chirodoc  Read Replies (1) of 518
 
here is an example of what i expect to see more of...

"Combining brachytherapy with another modality, such as hyperthermia, may improve results."

Hematol Oncol Clin North Am 1999 Jun;13(3):635-50, viii

Brachytherapy for brain tumor.

Suh JH, Barnett GH
Department of Radiation Oncology, Cleveland Clinic Foundation, Ohio, USA.

[Medline record in process]

Brachytherapy delivers high doses of radiation to brain tumors while sparing normal surrounding tissue. It may be used as a primary treatment, an adjuvant treatment, or as therapy for recurrence of some malignant gliomas, low-grade astrocytomas, meningiomas, metastases, and pediatric brain tumors. Each of the three principal types of brachytherapy (high dose rate, low dose rate, and intracavitary) has advantages and disadvantages. Combining brachytherapy with another modality, such as hyperthermia, may improve results. Although radiosurgery is supplanting brachytherapy for many indications, brachytherapy remains a viable option. This article discusses the radiobiology, procedures, clinical applications, and outcomes of brachytherapy in managing brain tumors
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext